Medications and Therapies

Video Library

  • Video Library

    Advancing Treatment for Atherosclerotic Cardiovascular Disease: Drug Therapies and Innovative Surgical Interventions

    This video explores advancements in treating Atherosclerotic Cardiovascular Disease (ASCVD), highlighting novel drugs like olezarsen and inclisiran, surgical interventions for aortic stenosis, and the efficacy of percutaneous coronary interventions (PCIs). It encapsulates findings from the American College of Cardiology’s 73rd annual expo.

    View

  • Running time: 35 minutes, 49 seconds

     

    00.16 Lp(a) structure and metabolism

    01.51 Elevated Lp(a) prevalence and risk of cardiovascular diseases

    02.38 Factors influencing Lp(a) level

    03.35 Physiological functions of Lp(a)

    04.12 Atherogenicity of Lp(a)

    04.56 Clinical implication of Lp(a) elevation

    05.25 Genetic variants associated with increased Lp(a) concentrations

    05.44 Association between high Lp(a) level and risk of various cardiovascular diseases

    07.43 Clinical implication of Lp(a) elevation at low LDL-C

    08.47 Lp(a) categories increases absolute baseline risk of traditional risk factors

    09.40 Is reducing Lp(a) physiologically safe?

    10.34 Strategies to lower Lp(a) level

    11.57 Future directions in Lp(a) research

    12.37 Summary

    Video Library

    Lp(a):What is it and its role in atherosclerosis

    In this video, Prof. Lale Tokgozoglu of Hacettepe University, former president of the European Atherosclerosis Society, discusses the structure, function, and genetics of Lp(a) and highlights the clinical implications of elevated Lp(a) levels. Using evidence from contemporary clinical studies, Prof. Tokgozoglu shares insights into approaches for lowering Lp(a) levels. Finally, challenges in the comprehensive understanding of the physiological and clinical implications of Lp(a) are discussed. Learning outcome – High levels of lipoprotein(a) increase the chances of experiencing heart attack, stroke, and aortic stenosis.

    View
View All Medications and Therapies Video Library

Infographics

View All Medications and Therapies Infographics

Articles

View All Medications and Therapies Articles

Case Studies

  • Case Studies

    August 2023

    Take this short quiz to test your knowledge on the recently published debate on dyslipidemias titled “Great debate: lipid-lowering therapies should be guided by vascular imaging rather than by circulating biomarkers”.

    CLICK HERE TO VIEW THE DEBATE.

    Eur Heart J. 2023 Jul 1;44(25):2292-2304. doi: 10.1093/eurheartj/ehad275

    Take

  • Case Studies

    Quiz of the month – May 2023

    Take this short quiz to test your knowledge on some of the latest peer-reviewed published literature related to ASCVD and Lipidology.

    Take

  • Case Studies

    Case Study – December 2022

    Our patient case study specially curated for you by our Faculty Member, Prof. Samer Ellahham on concerns about statin associated Diabetes Mellitus.

    Case Study: RS is a 64-year-old Male having dyslipidemia.

     

    Vital parameters:

    BP 144/87 mm Hg

    Low-density lipoprotein cholesterol (LDL-C) 112 mg/dL

    High-density lipoprotein cholesterol (HDL-C) of 47 mg/dL

    Triglycerides 190 mg/dL

    (-) tobacco, (-) alcohol

    Body mass index (BMI) 33 kg/m2

     

    Medication:

    Valsartan 80 mg/d

     

    Family history:

    Father developed type 2 diabetes mellitus (T2DM) and ASCVD at age 58

     

    Labs:

    Fasting blood glucose 103 mg/dL

    HbA1C 5.8%

    Serum Creatinine 1.1 mg/dL

    Urinary analysis within normal limits

     

     

    RS reports that he is reluctant to take statins as they cause diabetes especially with his family history.

    Read More
View All Medications and Therapies Case Studies